What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?

Published:2019-01-03 Issue:3 Volume:115 Page:e26-e31
ISSN:0008-6363
Container-title:Cardiovascular Research
language:en
Short-container-title:

Author:

Banach Maciej¹²³,Penson Peter E⁴

Affiliation:

1. Department of Hypertension, Medical University of Lodz, Zeromskiego 113, Lodz, Poland

2. Polish Mother’s Memorial Hospital Research Institute (PMMHRI), Lodz, Poland

3. Cardiovascular Research Centre, University of Zielona Gora, Zielona Gora, Poland

4. School of Pharmacy & Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK

Publisher

Oxford University Press (OUP)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine,Physiology

Link

http://academic.oup.com/cardiovascres/article-pdf/115/3/e26/29816357/cvy301.pdf

Reference27 articles.

1. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia;Abifadel;Nat Genet,2003

2. Evolocumab and clinical outcomes in patients with cardiovascular disease;Sabatine;N Engl J Med,2017

3. Alirocumab and cardiovascular outcomes after acute coronary syndrome;Schwartz;N Engl J Med,2018

4. Overview of the current status of familial hypercholesterolaemia care in over 60 countries—the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC);Atherosclerosis,2018

5. Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions;Penson;J Cachexia Sarcopenia Muscle,2018

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Could siRNA therapeutics change the way we treat dyslipidemia?;Expert Opinion on Biological Therapy;2024-05-03

2. The Use of CRISPR-Cas9 Genetic Technology in Cardiovascular Disease: A Comprehensive Review of Current Progress and Future Prospective;Cureus;2024-04-08

3. First-in-human gene editing for lipid lowering: the initial results;Cardiovascular Research;2024-03

4. Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP);Progress in Cardiovascular Diseases;2023-07

5. Modern possibilities of intensive treatment of dyslipidemia and gaps in its control: literature review;CardioSomatics;2023-04-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3